Harmony Biosciences HRMY
$32.59 −$0.39 (-1.18%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $32.59 0.00%
Open$32.68
Prev close$32.98
Day range$32.51 – $33.43
Volume582.6K
Market cap$1.91B
P/E (TTM)10.8
Dividend yield–
HRMY Stock News
Headlines matching Harmony Biosciences or the HRMY ticker, most recent first.
- Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $51
- Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50
- A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $30 to $55
- Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $39 Positive
- Wolfe Research Initiates Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $60
- H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $55
- Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $51 Positive
- Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50
- Goldman Sachs Upgrades Harmony Biosciences(HRMY.US) to Hold Rating, Raises Target Price to $37 Positive
- Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $45
- Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)
- Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $36 Positive
- Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $45 Positive
- Piper Sandler Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Cuts Target Price to $46 Negative
- Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $72 Positive
No comments yet — be the first to weigh in on HRMY.
Sign in to join the discussion.